These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 35892906)

  • 21. RYR2 Channel Inhibition Is the Principal Mechanism of Flecainide Action in CPVT.
    Kryshtal DO; Blackwell DJ; Egly CL; Smith AN; Batiste SM; Johnston JN; Laver DR; Knollmann BC
    Circ Res; 2021 Feb; 128(3):321-331. PubMed ID: 33297863
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An International Multicenter Evaluation of Inheritance Patterns, Arrhythmic Risks, and Underlying Mechanisms of
    Ng K; Titus EW; Lieve KV; Roston TM; Mazzanti A; Deiter FH; Denjoy I; Ingles J; Till J; Robyns T; Connors SP; Steinberg C; Abrams DJ; Pang B; Scheinman MM; Bos JM; Duffett SA; van der Werf C; Maltret A; Green MS; Rutberg J; Balaji S; Cadrin-Tourigny J; Orland KM; Knight LM; Brateng C; Wu J; Tang AS; Skanes AC; Manlucu J; Healey JS; January CT; Krahn AD; Collins KK; Maginot KR; Fischbach P; Etheridge SP; Eckhardt LL; Hamilton RM; Ackerman MJ; Noguer FRI; Semsarian C; Jura N; Leenhardt A; Gollob MH; Priori SG; Sanatani S; Wilde AAM; Deo RC; Roberts JD
    Circulation; 2020 Sep; 142(10):932-947. PubMed ID: 32693635
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Clinical challenges in the management of catecholaminergic polymorphic ventricular tachycardia in children].
    Ge HY; Li XM; Jiang H; Zhang Y; Liu HJ; Zheng XC; Li MT
    Zhonghua Er Ke Za Zhi; 2017 Dec; 55(12):926-931. PubMed ID: 29262473
    [No Abstract]   [Full Text] [Related]  

  • 24. A large deletion in RYR2 exon 3 is associated with nadolol and flecainide refractory catecholaminergic polymorphic ventricular tachycardia.
    Kohli U; Aziz Z; Beaser AD; Nayak HM
    Pacing Clin Electrophysiol; 2019 Aug; 42(8):1146-1154. PubMed ID: 30912151
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Implantable cardioverter-defibrillator use in catecholaminergic polymorphic ventricular tachycardia: A systematic review.
    Roston TM; Jones K; Hawkins NM; Bos JM; Schwartz PJ; Perry F; Ackerman MJ; Laksman ZWM; Kaul P; Lieve KVV; Atallah J; Krahn AD; Sanatani S
    Heart Rhythm; 2018 Dec; 15(12):1791-1799. PubMed ID: 30063211
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Different responses to exercise between Andersen-Tawil syndrome and catecholaminergic polymorphic ventricular tachycardia.
    Inoue YY; Aiba T; Kawata H; Sakaguchi T; Mitsuma W; Morita H; Noda T; Takaki H; Toyohara K; Kanaya Y; Itoi T; Mitsuhashi T; Sumitomo N; Cho Y; Yasuda S; Kamakura S; Kusano K; Miyamoto Y; Horie M; Shimizu W
    Europace; 2018 Oct; 20(10):1675-1682. PubMed ID: 29309601
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Catecholaminergic polymorphic ventricular tachycardia: electrocardiographic characteristics and optimal therapeutic strategies to prevent sudden death.
    Sumitomo N; Harada K; Nagashima M; Yasuda T; Nakamura Y; Aragaki Y; Saito A; Kurosaki K; Jouo K; Koujiro M; Konishi S; Matsuoka S; Oono T; Hayakawa S; Miura M; Ushinohama H; Shibata T; Niimura I
    Heart; 2003 Jan; 89(1):66-70. PubMed ID: 12482795
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bradycardia Is a Specific Phenotype of Catecholaminergic Polymorphic Ventricular Tachycardia Induced by RYR2 Mutations.
    Miyata K; Ohno S; Itoh H; Horie M
    Intern Med; 2018 Jul; 57(13):1813-1817. PubMed ID: 29434162
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Flecainide suppresses defibrillator-induced storming in catecholaminergic polymorphic ventricular tachycardia.
    Hong RA; Rivera KK; Jittirat A; Choi JJ
    Pacing Clin Electrophysiol; 2012 Jul; 35(7):794-7. PubMed ID: 22553997
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ventricular arrhythmia suppression with ivabradine in a patient with catecholaminergic polymorphic ventricular tachycardia refractory to nadolol, flecainide, and sympathectomy.
    Kohli U; Aziz Z; Beaser AD; Nayak HM
    Pacing Clin Electrophysiol; 2020 May; 43(5):527-533. PubMed ID: 32259298
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Role of Flecainide in the Management of Catecholaminergic Polymorphic Ventricular Tachycardia.
    Lieve KV; Wilde AA; van der Werf C
    Arrhythm Electrophysiol Rev; 2016 May; 5(1):45-9. PubMed ID: 27403293
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical and genetic profile of catecholaminergic polymorphic ventricular tachycardia in Hong Kong Chinese children.
    Yu TC; Liu AP; Lun KS; Chung BH; Yung TC
    Hong Kong Med J; 2016 Aug; 22(4):314-9. PubMed ID: 27256466
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Deadly emotional argument: Sudden cardiac death in catecholaminergic polymorphic ventricular tachycardia (CPVT).
    Violano M; Poller W; Abraham MR; Huemer M; Scheinman M; Landmesser U; Heidecker B
    Int J Cardiol Heart Vasc; 2022 Aug; 41():101062. PubMed ID: 35663620
    [No Abstract]   [Full Text] [Related]  

  • 34. Accelerated sinus rhythm prevents catecholaminergic polymorphic ventricular tachycardia in mice and in patients.
    Faggioni M; Hwang HS; van der Werf C; Nederend I; Kannankeril PJ; Wilde AA; Knollmann BC
    Circ Res; 2013 Feb; 112(4):689-97. PubMed ID: 23295832
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Co-Phenotype of Left Ventricular Non-Compaction Cardiomyopathy and Atypical Catecholaminergic Polymorphic Ventricular Tachycardia in Association With R169Q, a Ryanodine Receptor Type 2 Missense Mutation.
    Nozaki Y; Kato Y; Uike K; Yamamura K; Kikuchi M; Yasuda M; Ohno S; Horie M; Murayama T; Kurebayashi N; Horigome H
    Circ J; 2020 Jan; 84(2):226-234. PubMed ID: 31875585
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Catecholaminergic polymorphic ventricular tachycardia: a model for genotype-specific therapy.
    Roston TM; Van Petegem F; Sanatani S
    Curr Opin Cardiol; 2017 Jan; 32(1):78-85. PubMed ID: 27861184
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CASQ2 variants in Chinese children with catecholaminergic polymorphic ventricular tachycardia.
    Li Q; Guo R; Gao L; Cui L; Zhao Z; Yu X; Yuan Y; Xu X
    Mol Genet Genomic Med; 2019 Nov; 7(11):e949. PubMed ID: 31482657
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Catecholaminergic polymorphic ventricular tachycardia: An exciting new era.
    Behere SP; Weindling SN
    Ann Pediatr Cardiol; 2016; 9(2):137-46. PubMed ID: 27212848
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A novel heterozygous mutation in cardiac calsequestrin causes autosomal dominant catecholaminergic polymorphic ventricular tachycardia.
    Gray B; Bagnall RD; Lam L; Ingles J; Turner C; Haan E; Davis A; Yang PC; Clancy CE; Sy RW; Semsarian C
    Heart Rhythm; 2016 Aug; 13(8):1652-60. PubMed ID: 27157848
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cardiac Transplantation for Refractory Catecholaminergic Polymorphic Ventricular Tachycardia.
    Roy S; Hong W; Wasilewski M; Ellenbogen KA
    JACC Case Rep; 2020 Sep; 2(11):1757-1761. PubMed ID: 34317051
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.